7-ethyl-2-piperazin-1-yl-6,7,8,9-tetrahydro-5H-pyrazino[2,3-d]azepine | 1143575-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-ethyl-2-piperazin-1-yl-6,7,8,9-tetrahydro-5H-pyrazino[2,3-d]azepine
• 英文别名: 7-ethyl-3-piperazin-1-yl-5,6,8,9-tetrahydropyrazino[2,3-d]azepine
• CAS: 1143575-98-7
• 化学式: C₁₄H₂₃N₅
• 分子量: 261.37
• InChiKey: WSWJWIFMOBUHNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  44.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  7-ethyl-6,7,8,9-tetrahydro-5H-pyrazino[2,3-d]azepin-2-ylamine 在 盐酸 、 copper(I) bromide 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 20.0h， 生成 7-ethyl-2-piperazin-1-yl-6,7,8,9-tetrahydro-5H-pyrazino[2,3-d]azepine
  参考文献：
  名称：

  COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

  摘要：

  本发明涉及新的药物组合，除了含有一种或多种PDE4抑制剂（1）外，还包含至少一种EP4受体拮抗剂（2），以及其用于治疗最好是呼吸道疾病，如慢性阻塞性肺疾病（COPD）、慢性鼻窦炎和哮喘等的用途。特别涉及那些含有至少一种EP4受体拮抗剂（2）的药物组合，除了一种或多种，最好是一种，PDE4通用式1的抑制剂，其中X为SO或SO2，但最好是SO，且其中R3表示一个可选择取代的、单环或双环、不饱和、部分饱和或饱和的杂环基团或一个可选择取代的、单环或双环杂环基团，其中R1和R2具有权利要求1中给出的含义，其制备和用于治疗呼吸道疾病的用途。

  公开号：

  US20130237527A1

文献信息

• HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES
  申请人：Pouzet Pascale

  公开号：US20100305102A1

  公开（公告）日：2010-12-02

  The invention relates to new dihydrothienopyrimidinesulphoxides of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl and wherein R 1 and R 2 have the meanings stated in claim 1, as well as pharmaceutical compositions which contain these compounds. These new dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

  该发明涉及公式1的新二氢噻吡嘧啶磺氧化物，以及其药理学上可接受的盐，其中X为SO或SO2，但最好为SO，其中R3表示一个可选择取代的、单环或双环的、不饱和的、部分饱和的或饱和的杂环，或一个可选择取代的、单环或双环的杂芳基，其中R1和R2具有权利要求1中所述的含义，以及含有这些化合物的药物组合物。这些新的二氢噻吡嘧啶磺氧化物适用于治疗呼吸道或胃肠道疾病，关节、皮肤或眼睛的炎症性疾病，外周或中枢神经系统疾病或癌症。
• DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS
  申请人：NICKOLAUS Peter

  公开号：US20120028932A1

  公开（公告）日：2012-02-02

  The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO 2 , but preferably SO, and wherein R 3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R 1 and R 2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

  本发明涉及包含除一个或多个PDE4抑制剂外，至少一个NSAID（非甾体抗炎药）的新药物组合，以及用于制备它们的方法以及它们在治疗呼吸道疾病（如COPD、慢性鼻窦炎和哮喘等）中的用途。该发明特别涉及那些药物组合，除了一个或多个，最好是一个一般式1中X为SO或SO2，但最好是SO，且其中R3表示一个可选择取代的、单环或双环、不饱和、部分饱和或饱和的杂环基团或一个可选择取代的、单环或双环杂芳基，其中R1和R2具有权利要求1中给出的含义，至少包含一个NSAID（2），其制备和用于治疗呼吸道疾病。
• Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists
  申请人：Nickolaus Peter

  公开号：US08877758B2

  公开（公告）日：2014-11-04

  The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

  本发明涉及新药物组合物，除了含有一种或多种PDE4抑制剂（1）之外，还包括至少一种EP4受体拮抗剂（2），以及用于治疗呼吸系统疾病，特别是COPD、慢性鼻窦炎和哮喘的用途。 本发明特别涉及那些含有至少一种EP4受体拮抗剂（2）和一种或多种，优选为一种，通式1的PDE4抑制剂的药物组合物，其中X为SO或SO2，但优选为SO，R3表示可选取代的单环或双环、不饱和、部分饱和或饱和的杂环基或可选取代的单环或双环杂芳基，其中R1和R2的含义如权利要求1所述，以及其制备方法和用于治疗呼吸系统疾病的用途。
• Drug combinations containing PDE4 inhibitors and NSAIDs
  申请人：Nickolaus Peter

  公开号：US08592400B2

  公开（公告）日：2013-11-26

  Drug combinations which contain a PDE4-inhibitor and a non-steroidal anti-inflammatory drug (NSAID), processes for preparing them, and their use in treating in particular respiratory complaints such as COPD, chronic sinusitis, and asthma. The PDE4 inhibitors of the drug combinations include compounds of general formula 1 wherein X is SO or SO2, but preferably SO, R3 is an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl, and R1 and R2 have the meanings given in claim 2.

  药物组合物包含PDE4抑制剂和非甾体抗炎药（NSAID），其制备过程以及它们在治疗特定呼吸问题，如COPD，慢性鼻窦炎和哮喘中的用途。药物组合物的PDE4抑制剂包括一般式1的化合物，其中X为SO或SO2，但最好为SO，R3为可选取代的单环或双环，不饱和，部分饱和或饱和杂环基或可选取代的单环或双环杂环芳基，R1和R2具有权利要求2中给出的含义。
• Heterocycle-substituted piperazino-dihydrothienopyrimidines
  申请人：Pouzet Pascale

  公开号：US09115142B2

  公开（公告）日：2015-08-25

  Dihydrothienopyrimidinesulphoxides of formula 1 wherein X is SO or SO2, R1 is H or C1-6-alkyl, R2 is H or an organic group as disclosed herein, and R3 is an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl, and the pharmacologically acceptable salts thereof, as well as pharmaceutical compositions which contain these compounds. These dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system, or cancers.

  化学式为1的二氢噻唑嘧啶磺氧化物，其中X为SO或SO2，R1为H或C1-6-烷基，R2为H或本文所披露的有机基团，R3为可选取代的单环或双环、不饱和、部分饱和或饱和的杂环或可选取代的单环或双环杂环芳基，以及其药学上可接受的盐，以及含有这些化合物的制药组合物。这些二氢噻唑嘧啶磺氧化物适用于治疗呼吸或胃肠疾病，关节、皮肤或眼部炎症性疾病，周围或中枢神经系统疾病或癌症。